We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Aug-2025
Active ingredients
durvalumab
Proposed indication
Imfinzi (durvalumab) is proposed to be used with a combination of chemotherapy drugs before and after surgery, and then on its own after surgery, to treat patients with gastric (stomach) cancer or gastroesophageal junction cancer (an aggressive, slow-growing cancer of the lower esophagus and stomach junction) that can be removed by surgery.
Application type
C (new indication)
Publication date
Aug-2025
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.